Drug intelligence / Profile preview

L-carnitine + piracetam

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

L-carnitine + piracetam is a fixed-dose combination of two agents, L-carnitine and piracetam, used primarily for their synergistic effects on fatigue, muscle strength, and mitochondrial protection. L-carnitine is a naturally occurring amino acid derivative involved in the transport of fatty acids into mitochondria for energy production. Piracetam is a nootropic agent that modulates cerebral metabolism by enhancing neuronal energy efficiency and restoring cortical cell function, thereby improving cognitive functions such as attention and memory. The combination has demonstrated efficacy in improving fatigue and muscular strength in patients with post-poliomyelitis syndrome (PPS) and may provide muscle-protective effects against statin-induced myalgia. Mechanistically, both agents protect against mitochondrial dysfunction through complementary actions[1][5][6].

Other names
L-carnitine and piracetamL-carnitine/piracetamlevocarnitine and piracetam
02

Targets

AMPAR (AMPA receptor)MPTP (Mitochondrial permeability transition pore)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)AChR (Acetylcholine receptor)SLC25A20 (Carnitine/acylcarnitine translocase)Neuraminidase

Beyond the preview

Go deeper on L-carnitine + piracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-carnitine + piracetam.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call